Skip to main content
Clinical Trials/DRKS00029279
DRKS00029279
Recruiting
Phase 2

Evaluation of Sonalleve MR-HIFU for Non-invasive Thermal Therapy of Facet-Joint Syndrome: Feasibility and Safety Clinical Study - HIFU-FACET

niversitätsklinikum Köln0 sites10 target enrollmentJune 21, 2022

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
M47.9
Sponsor
niversitätsklinikum Köln
Enrollment
10
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 21, 2022
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
niversitätsklinikum Köln

Eligibility Criteria

Inclusion Criteria

  • 1\. Male or female, \> 18 years old
  • a. Females of childbearing potential (FCBP) must have a negative serum pregnancy test within 7 days prior to MR\-HIFU treatment
  • b. and must agree to use effective contraceptive birth control measures (Pearl Index \< 1\) during the course of the trial. A female patient is considered to be of childbearing potential unless she is above 50 years of age and naturally amenorrhoeic for \= 2 years, or unless she is surgically sterile.
  • 2\. Patients with chronic LBP refractory to medical and/or physical treatment.
  • 3\. Clinical diagnosis of Lumbar Facet Joint Syndrome (radiologic signs of facet joint osteoarthritis and/or positive diagnostic infiltration of suspected facet joint levels)
  • 4\. Eligibility for MR imaging and MR\-HIFU sessions
  • 5\. Eligibility for general anesthesia and/or sedation
  • 6\. Intact skin and soft tissue over treatment zone
  • 7\. Facet Joint Anatomy clearly identifiable, targetable, and reachable in MRI for treatment
  • 8\. Patients able to discontinue all current analgesic medications for a minimum 48\-hour (or \=5 half\-lives of the particular analgesic, whichever is greater) prior to baseline assessment.

Exclusion Criteria

  • Exclusion Criteria
  • 1\. Spinal implants
  • 2\. Treatment target zone \< 10mm from the skin
  • 3\. Pregnant female patients
  • 4\. Breastfeeding female patients
  • 5\. Body weight \> 140 kg
  • 6\. Systemic and/or local infections
  • 7\. Moderate to high grade of spinal instability (Grade II – IV)
  • 8\. MRI contrast agent contraindications
  • 9\. Any MR\-unsafe implant or pacemaker. Any MR\-conditional implant that requires scanning with less than 3 Tesla or adjustments to the scan protocol.

Outcomes

Primary Outcomes

Not specified

Similar Trials